Exact Mass: 229.12487639999998
Exact Mass Matches: 229.12487639999998
Found 143 metabolites which its exact mass value is equals to given mass value 229.12487639999998
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Butenylcarnitine
Butenylcarnitine is an acylcarnitine. More specifically, it is an butenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Butenylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine Butenylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular Butenylcarnitine is elevated in the blood or plasma of individuals with maternal obesity/prepregnant obesity of mothers (PMID: 31975597). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
3-Butenylcarnitine
3-Butenylcarnitine is an acylcarnitine. More specifically, it is an but-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Butenylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 3-Butenylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular 3-Butenylcarnitine is elevated in the blood or plasma of individuals with maternal obesity/prepregnant obesity of mothers (PMID: 31975597). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(1H-INDOL-6-YL)(PIPERAZIN-1-YL)METHANONE
C13H15N3O (229.12150599999998)
2-PHENYL-5-(PIPERIDIN-4-YL)-1,3,4-OXADIAZOLE
C13H15N3O (229.12150599999998)
1H-indol-2-yl(piperazin-1-yl)methanone
C13H15N3O (229.12150599999998)
N-ethyl-1-(4-methoxyphenyl)propan-2-amine,hydrochloride
(2S)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid
3-((tert-Butoxycarbonyl)amino)cyclopentanecarboxylic acid
2-(6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[4,3-A]AZEPIN-3-YL)PHENOL
C13H15N3O (229.12150599999998)
4-(diethylamino)quinazoline-6-carbaldehyde
C13H15N3O (229.12150599999998)
methyl 1-(2-ethoxy-2-oxoethyl)piperidine-4-carboxylate
2,5-DIMETHYL-4-METHYLCARBAMOYL-1-PHENYLIMIDAZOLE
C13H15N3O (229.12150599999998)
N-methyl-1-[3-(6-methylpyrazin-2-yl)oxyphenyl]methanamine
C13H15N3O (229.12150599999998)
tert-butyl 4-formyl-4-hydroxypiperidine-1-carboxylate
Methyl 2-((tert-butoxycarbonyl)amino)pent-4-enoate
(R)-TERT-BUTYL 2-(2-OXOETHYL)MORPHOLINE-4-CARBOXYLATE
N-methyl-1-[4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine
C13H15N3O (229.12150599999998)
(2S)-1-(TERT-BUTOXYCARBONYL)-5-METHYLPYRROLIDINE-2-CARBOXYLIC ACID
3-((tert-Butoxycarbonyl)amino)-3-cyclopropylpropanoic acid
3-Oxo-3-(4-phenyl-1-piperazinyl)propanenitrile
C13H15N3O (229.12150599999998)
(R)-2-((TERT-BUTOXYCARBONYL)AMINO)-2-METHYLPENT-4-ENOIC ACID
2-(1-(TERT-BUTOXYCARBONYL)PYRROLIDIN-2-YL)ACETIC ACID
(S)-3-(FMOC-AMINO)-5-METHYLHEXANOIC ACID, FMOC-L-SS-HOMOLEUCINE
C13H15N3O (229.12150599999998)
(s)-(-)-3-tert-butoxycarbonyl-4-formyl-2,2-dimethyl-1,3-oxazolidine
2-[(6-METHYL-2-PHENYL-4-PYRIMIDINYL)AMINO]-ETHANOL
C13H15N3O (229.12150599999998)
(1S,2R)-Boc-2-amino-1-cyclopentane carboxylic acid
cis-2-(tert-Butoxycarbonylamino)-1-cyclopentanecarboxylic acid
(1R,3S)-N-Boc-1-Aminocyclopentane-3-carboxylic acid
tert-butyl 3-(2-methoxy-2-oxoethyl)azetidine-1-carboxylate
(4-FORMYL-PHENYL)-CARBAMICACIDTERT-BUTYLESTER
C13H15N3O (229.12150599999998)
1-[3-AMINO-4-(4-METHYL-4H-PYRAZIN-1-YL)-PHENYL]-ETHANONE
C13H15N3O (229.12150599999998)
(R)-2-(1-(tert-Butoxycarbonyl)pyrrolidin-2-yl)acetic acid
2-CHLORO-N-(2,3,3-TRIMETHYL-BICYCLO[2.2.1]HEPT-2-YL)-ACETAMIDE
Boc-L-Cyclobutylglycine
Boc-L-cyclobutylglycine is a glycine derivative that can be used for PI3K inhibitor synthesis[1].
N,N-dimethyl 1-benzyl-1H-imidazole-5-carboxamide
C13H15N3O (229.12150599999998)
4-ethoxy-2-methyl-5-propan-2-ylaniline,hydrochloride
PYRROLIDINE-1,2-DICARBOXYLICACID1-TERT-BUTYLESTER2-METHYLESTER
(S)-1-BOC-PYRROLIDINE-3-CARBOXYLIC ACID METHYL ESTER
(S)-Methyl 2-((tert-butoxycarbonyl)amino)pent-4-enoate
(R)-Methyl 2-((tert-butoxycarbonyl)amino)pent-4-enoate
(2S,5R)-N-BOC-5-METHYLPYRROLIDINE-2-CARBOXYLICACID
Methyl cis-3-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)cyclobuta necarboxylate
2-(2,5-DIMETHYL-1H-PYRROL-1-YL)BENZOHYDRAZIDE
C13H15N3O (229.12150599999998)
4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YLCARBONYL)PIPERIDINE
C13H15N3O (229.12150599999998)
(S)-2-Benzyl-5-(pyrrolidin-2-yl)-1,3,4-oxadiazole
C13H15N3O (229.12150599999998)
6-Benzyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3(2H)-one
C13H15N3O (229.12150599999998)
methyl-2-(tert-butoxycarbonylamino)-2-cyclopropylacetate
Ethyl 3-hydroxy-1-oxa-8-azaspiro[4.5]decane-8-carboxylate
3-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine
C13H15N3O (229.12150599999998)
(1R,3S)-3-{[(tert-butoxy)carbonyl]amino}cyclopentane-1-carboxylic acid
(1S,3S)-3-{[(tert-butoxy)carbonyl]amino}cyclopentane-1-carboxylic acid
(1R,3R)-3-{[(tert-butoxy)carbonyl]amino}cyclopentane-1-carboxylic acid
2-TERT-BUTOXYCARBONYLAMINO-CYCLOPENTANECARBOXYLIC ACID
TERT-BUTYL 4-FORMYL-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE
(2S,5S)-N-BOC-5-METHYLPYRROLIDINE-2-CARBOXYLICACID
(1H-INDOL-3-YL)(PIPERAZIN-1-YL) METHANONE
C13H15N3O (229.12150599999998)
2-imidazol-1-yl-4-methyl-6-pyrrolidin-2-ylpyrimidine
ethyl 1-((tert-butoxycarbonyl)amino)cyclopropanecarboxylate
3-(4-methoxyphenyl)-4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridine
C13H15N3O (229.12150599999998)
(S)-TERT-BUTYL 2-(2-OXOETHYL)MORPHOLINE-4-CARBOXYLATE
4-O-tert-butyl 2-O-methyl (2R,4S)-pyrrolidine-2,4-dicarboxylate
3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
1-PHENYL-3-(PYRROLIDIN-1-YL)-1H-PYRAZOL-5(4H)-ONE
C13H15N3O (229.12150599999998)
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
ethyl 2-{[(tert-butoxy)carbonyl]amino}cyclopropane-1-carboxylate
1-Piperidinecarbothioamide,4-(4-morpholinyl)-
C10H19N3OS (229.12487639999998)
3-Methoxy-4-oxo-1-piperidinecarboxylic acid 1,1-dimethylethyl ester
N-(4,6,7-trimethylquinazolin-2-yl)guanidine
A2B receptor antagonist 2 (compound 18) is an adenosine receptor A2B antagonist, with Ki values of 2.30 μM, 6.8 μM and 3.44 μM for rA1, rA2A and hA2B, respectively[1].
6,7,8,9-tetrahydro-5H-carbazole-3-carbohydrazide
C13H15N3O (229.12150599999998)
(R)-crotonylcarnitine
A O-butenoyl-L-carnitine in which the acyl group is specified as crotonyl.
[6-Methoxy-2,3,4,9-tetrahydro-carbazol-(1E)-ylidene]-hydrazine
C13H15N3O (229.12150599999998)
O-butenoylcarnitine
An O-acyl carnitine in which the acyl group specified is butenoyl.
O-butenoyl-L-carnitine
An O-acyl-L-carnitine in which the acyl group specified is butenoyl in which the position of the double bond is unspecified.